While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. We may also receive compensation if you click on certain links posted on our site. We may receive compensation from our partners for placement of their products or services. While we are independent, the offers that appear on this site are from companies from which receives compensation. and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.į is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions.
Beem stock price target license#
license agreement with Sana Biotechnology, Inc.
Beem stock price target trial#
The company has an alliance with Boston Children's Hospital a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc. It also develops therapies for alpha-1 antitrypsin deficiency ocular diseases and other liver, muscle, and central nervous system disorders. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia BEAM-102 for the treatment of sickle cell disease and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. Beam Therapeutics Inc overviewīeam Therapeutics Inc. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns). The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.6025. volatility (beta: 1.00) Low Highīeta is a measure of a share's volatility in relation to the market. A popular way to gauge a stock's volatility is its "beta". Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $27.77 up to $138.5219. Beam Therapeutics Inc share price volatility We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months. TTM: trailing 12 months Beam Therapeutics Inc share dividends Crypto assets through eToro USA LLC.īeam Therapeutics Inc financials Revenue TTM We chose Tastyworks for this category because it offers a wide range of derivative trading options, including futures, future e-micros and options, along with live trading shows and a platform packed with advanced charting tools and indicators.Ĭlient disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
Beem stock price target free#
We chose SoFi for this category because it offers a free robo-advisor as well as commission-free stocks. These social features are a great way for new investors to learn about the market and follow trends. It also lets you see trades that other investors are making and discuss investment strategies on the app.
We chose eToro for this category because it offers commission-free stocks and an easy-to-use mobile app.
We encourage you to compare stock platforms to find one that's best for your particular budget and goals. We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs.
0 kommentar(er)
